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1. Introduction
A traditional experimental design is to compare treatments in a
one-way treatment structure with a completely randomized design
structure where each experimental unit is subjected to one treatment.
Since each experimental unit is subjected to only one treatment, direct
treatment effects, the effect a treatment has on the subject's response,
is measured through among- subjects comparisons. In an experiment
involving t treatments, N experimental units are randomly assigned to t
groups with n. experimental units in group i, i-1, 2, ..., t and N -
t
S n.
.
The classical model for analyzing a one-way treatment structure
i-1
in a completely randomized design structure is
Y.
.
- u + r. + e.
.
,
d 1)
where ^ - overall mean,
T. - mean effect of treatment i, and
e. ,- random error.
For inference purposes, it is assumed that e.. - i.i.d. N (0, a ). The
estimate of the error variance is obtained from the variation among
subjects, within treatment groups. Often, there is a relatively large
variation among subjects within a treatment group, which can inhibit the
chance of detecting treatment differences.
An alternative experimental design, is to allow each subject to go
through a sequence of treatments, where each subject is its own
"control". Such a design is called a crossover design. This
experimental design can be used in a wide variety of applications in
experimental research, from agriculture to testing biological assays to
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marketing and sociological experimentation. A crossover design
incorporates a repeated measures design structure, where treatments are
administered in a sequence over time to each subject. Thus, comparisons
of treatments are based on within-subject comparisons. The inherent
variation among responses within a subject is often smaller than the
variation among subjects, making this class of designs more appealing to
researchers. When this is the case, the crossover design provides more
precise estimates of treatment effects than those from a one-way
treatment structure in a completely randomized design. Due to the
smaller variation fewer experimental units are required to detect
treatment differences of a fixed size with a crossover design compared
to a one-way design. However, when different treatments are applied in
succession to the same experimental unit, carryover, or residual effects
from the preceding treatment can affect the present treatment's
response. A carryover treatment effect is the effect of a treatment
which carries over beyond the period of application which can bias
subsequent estimates of direct treatment effects. The main focus of
discussion is on one-period carryover effects, i.e., where the effect of
a treatment can extend one more time period. Other residual effects
will be discussed briefly.
2. Crossover Designs
Crossover designs involve constructing s sequences of t treatments
in which subjects are randomly assigned to one of the sequences of
treatments. Treatments are applied to the subjects in a specific
sequence over periods of time. Each period should be of sufficient
length to allow expression of the treatment effects and also long enough
so that the effect of treatment does not go beyond the period. When
there is a risk of carryover effects, it is possible, in some
situations, to separate the time intervals in which treatments are
applied by enough time for carryover effects to die out, typically
called washout periods. This extends the length of the experiment and
is impractical in many situations. Treatment carryover effects may
affect future treatment responses in one of two ways
. If the carryover
effects are equal, then the average treatment response will increase or
decrease by a fixed amount, resulting in the same power for detecting
treatment differences as if there were no carryover. If differential
carryover effects occur, adjusting treatment means for carryover effects
can be accomplished by using a set of sequences balanced for specified
types of carryover effects. One-period carryover, or first order
carryover, is a residual treatment effect which affects only the next
treatment's response in the sequence. A set of sequences is balanced
for a one-period carryover, if each treatment is preceded equally often
by each other treatment and each treatment occurs equally often in each
period. Similarly, second, third k*^ order carryover effects may
occur lasting for two, three, and k periods, respectively, beyond the
period of application. Unless carryover effects are equal, direct
treatment effects are biased if the analysis does not incorporate an
adjustment for the differing carryover effects.
In the simplest case, two treatments in a two-period crossover
design, involves two sequences of treatments, treatment A followed by B
and treatment B followed by A with possibly a washout between periods.
Subjects are assigned completely at random to sequences of treatments
such that one-half of the experimental units receive treatment A and the
l»WW»>
other one-half receive treatment B in the first period. The
experimental unit receiving treatment A (or B) in period one then
receives treatment B (or A) in period two, thus the name crossover
design. One response is obtained per subject per period in a standard
crossover experiment, although this response could be an average of
several measurements taken during the period.
Table 1 is a layout of the data for a two-period crossover design
using notation from Grizzle (1965), where S.. denotes subiect i in
sequence i and Y,
., denotes the observed response of subject j in
sequence i to the treatment administered during period k.
Table 1
.
Layout of the Data for a Two-Period Crossover Design
PERIOD SEQUENCE SUBJECT
11'
111'
112'
.
,
S
In,
In^l
ln22
SEQUENCE
B
A
SUBJECT
^21'
212'
.
,
S
2n„
^211
''2n2l
2n^
Since each treatment is observed on the sane subject, a repeated
measures design with two sizes of experimental units is generated. Each
subject, the larger experimental unit, is assigned to a treatment
sequence completely at random. The experimental design for period, the
smaller experimental unit, is a one-way treatment structure with levels
A and B in a randomized complete block design structure where the
subjects are the blocks. The appropriate model for a two -period
crossover design is,
\jkt- ''ikt ^ «j(i) ^ ^Ijkf <2.1)
where
^'^y^ - mean effect of treatment t within sequence 1 at time k,
f^/j^s - random error of subject j within sequence 1, and
fj^^j^^ - random error associated with the period within the
subject.
For inference purposes, assume ?•,.^ - i.i.d. N(0,ap, £.., - 1.1. d.
2
N(0,(T^), when i,,,^ and
'-.vt- ^re independent.
Since there are two sizes of experimental units, the subjects and
the periods, there are two types of comparisons, between- subject
comparisons and within- subject comparisons. The sequence effect, the
residual effect, and the treatment by period interaction effect are
equivalent for the two-period crossover design, each comparing the
carryover effects for the two treatments. The treatment effect, a
within- subject comparison, is equivalent to the period by sequence
Interaction effect, and the period effect, also a within- subject
comparison, is equivalent to the treatment by sequence interaction
effect.
A reparameterized model with carryover effects Is,
\jkt- '^ ^ «j(i) + -k ^ 't ^ Vi(k-1)A
^ Vi(k-1)B + 'ijkf <2-2)
where ii - overall mean,
^i/j^N ~ random effect of subject j within sequence 1,
IT,
- mean effect of period k.
T =- mean direct effect of treatment t,
X^ = mean carryover effect of treatment t,
1 if k-2 and treatment t occurs in period one
i(k-l)t of sequence i,
otherwise, and
«• •,
j^
- random error associated with the period within the
subject,
where j - 1, 2 n^^; i,k - 1,2; t - A,B; f - i.i.d. N (0, ah,
2
^iiVr - i.i.d. N (0, a ), and the ^.,., are independent of the £.., .IJKC £ j(i) - ijkt
Based on the above distributional properties and assumptions , the
sources of variation, associated degrees of freedom, and quantities
proportional to the noncentrality parameters are given in Table 2.
Table 2. ANOVA Table for the Two-Treatment Two-Period Crossover Design
Source of Variation
Between Subject Analysis
Carryover or Sequence
Subject(Sequence)
Within Subject Analysis
Period
Treatment
Error
Total
1
S (n -1)
i-1
S (n -1)
i-1 ^
2
2 2 n. -
i-1 ^
Noncentrality
Parameter
<VV
The tests for direct treatment effects assumes no period by
treatment interaction. No period by treatment interaction, equivalent
to carryover effects and sequence effects , implies that the
effectiveness of one treatment does not change relative to the other as
subjects go from period one to period two. Direct treatment effects are
estimated by averaging the corresponding treatment responses of period
one and period two. If the assumption of no period by treatment
interaction is not satisfied, then there is a difference in the
reliability of the results in the different periods. Each treatment in
a two -period crossover design appears equally often in both periods and
both sequences, but each treatment does not appear in every possible
treatment-period pairing. Treatment A is in period two only in the
second sequence, so it is possible only to observe how treatment A
responds in period two when it is preceded by treatment B. If A reacts
differently in period two, it could be due to the order of testing
(sequence) or to the time of testing (period). It is impossible to
determine how much, if any, of the overall difference between the two
treatments is due to the treatments or to the treatment interaction with
period and sequence effects. In period one, the responses for
treatments A and B can be compared, even if differential carryover
exists, because of the random assignment of subjects to the two
sequences. In period two, if there is differential carryover, the
subjects in each sequence start in a dissimilar state due to the
different experience that occurred in period one. There is no way to
adjust the treatments means for the differential carryover effects from
the within-subject analysis since the carryover effects are estimated
from the between- subject analysis. In this case, an appropriate
analysis is a two sample t-test performed on data in period one only,
assuming normality. In this case, the expected treatment response is
assumed to be the same, except for a random component, for all subjects.
In addition, the expected treatment response is assumed to be the same
regardless of which period the treatment is administered in. As an
alternative, treatment comparisons can be made using a combined estimate
of between- subject and within- treatment comparisons as shown by Milliken
and Johnson (1984). The response to treatment in period one in the two
sequence groups may be compared by a Wilcoxon two sample test if non-
normality is a concern.
Crossover designs with more than two periods are similar to two
period designs in that there are two sizes of experimental units, two
error terms, and two levels of the analysis. In the following sections,
concentration is focused on designs in which three periods are used. A
model to describe a three -period crossover is,
^ijkt- /^ + «i ^ ?j(i) + -k ^ ^t ^ Vi(k-1)A
^ Vi(k-1)B ^ Vi(k-l)C ^ 'ijkf (2.3)
where ii - overall mean,
K. — mean effect of sequence i,
?j/j^s - random error of subject j within sequence i,
iTj^ - mean effect of period k,
T
- effect of treatment t,
A^ - mean residual effect of treatment t,
1 if treatment t occurs in period (k-1) of
^i(k-l)t " \
sequence i, k - 2,3,
otherwise, and
£j^jj^ - random error associated with the period within the
subject.
3
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Latin Square
The two sequences in the two-period two-treatment crossover design
form a Latin square. The traditional Latin square design structure can
be employed in constructing crossover designs in which three or more
treatments are to be studied. For crossover designs, the row blocks of
the Latin square are the sequences and the column blocks are the
treatment periods. Treatments are then assigned to periods for each
sequence such that each treatment occurs once in each period and once in
each sequence. A standard Latin square, defined by Federer (1955), is
one in which the first row and the first column are ordered
alphabetically or numerically. The procedure to construct a standard
Latin square is as follows:
1
.
Number the treatments
, i - 1 t
.
2. The first row of the square consists of a sequential ordering
of the treatments, i.e., 1 2 3 ... t.
3. A one step cyclic permutation of a sequence of treatments is
one which moves the first treatment in the sequence to the
extreme right, simultaneously moving all other treatments one
position to the left. i.e., Row two of the Latin square Is
2 3 4 t 1.
The analysis of variance model for a Latin square sequence
structure where subjects are assigned to sequences in a completely
randomized design structure is the same as that defined in model (2.3).
It is assumed that the effects of all three factors are additive and
that treatment effects do not interact with sequence and period effects.
The sources of variation and the associated degrees of freedom for the
Latin square model are given in Table 3
.
Table 3. ANOVA Table for the Latin Square Design
Source of Variation df
Between Subject Analysis
Sequence t - 1
t
Subject(Sequence) S (n.-l)
i-1 ^
Within Subject Analysis
Period t - 1
Treatment t - 1
Carryover t - 1
t
Error S n (t-1) - 3(t-l)
i-1 ^
t
Total t (S n.) - 1
i-1 ^
4. Williams Square
Crossover designs balanced for one-period carryover effects were
developed by E. J. Williams (1949). These designs were devised in order
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to measure both direct treatment and carryover effects from the within-
subject comparisons for three or more treatments over three or more
periods of time. Williams defines a crossover design to be balanced for
one-period carryover effects when two conditions are satisfied. First,
each treatment is preceded equally often by each other treatment.
Second, each treatment must occur equally often in each period, in order
of application to the subjects. These conditions for balancing require
the number of sequences to be a multiple of the number of treatments.
When there are t treatments, there are t(t-l) ordered pairs of
treatments. Since there are (t-1) adjacent pairs in each sequence, the
first condition requires a multiple of t sequences for all ordered pairs
to occur equally often. The second condition is also satisfied by a
multiple of t sequences.
Williams shows that when the number of treatments is even, a design
balanced for one-period carryover effects can be achieved with a minimum
of t sequences. When the number of treatments is odd, a minimum of 2t
sequences is needed to balance the design. Balanced designs can be
constructed from the cyclic Latin square of size t in which the rows
represent the sequences, the columns the periods, and the symbols the
treatments
.
One square is required when the number of treatments is
even and two squares are required when the number of treatments is odd.
Williams presents methods of balancing designs for one-period and two-
period carryover effects. Two-period carryover effects occur when the
effect of a treatment carries two periods beyond the application. The
original construction of these balanced designs is fairly complicated.
A more simple method of construction for designs balanced for one-period
carryover is given in Bradley (1958) for an even ntimber of treatments.
11 .
Sheehe and Bross (1961) present the following extension of Bradley's
results in which construction of designs balanced for one-period
carryover can be created for both even and odd numbers of treatments
.
1. Number the treatments, i - 1 ... t.
2. Start with a cyclic t x t Latin square in which the sequence
of treatments in the 1 row is i, i+1 t, 1, 2
i-1.
3. Interlace each row of the cyclic Latin square with its own
reverse order sequence (its mirror image). For example, if t-3
the first row of the cyclic Latin square is 1,2,3. Its mirror
image is 3,2,1. When this is interlaced with the first row of
the original square, the structure is 1,3,2,2,3,1.
4. Form two t x t Latin squares by vertically cutting this t x 2t
rectangle down the middle. The columns of each square
represent the order of application from left to right, the rows
represent the sequences, and the treatments are the elements
within each square.
For Williams square sequence structures, the treatments are assigned
numbers at random, and the sequences are randomized. For t='3 , the
following two squares form a design balanced for one-period carryover
effects
.
Sequence 1: 1 3 2
Sequence 2 : 2 1 3
Sequence 3: 3 2 1
and
Sequence 4
Sequence 5
Sequence 6
2 3 1
3 12
12 3
12
For t-4, the following squares are formed:
Sequence 1
Sequence 2
Sequence 3
Sequence 4
14 2 3
2 13 4
3 2 4 1
4 3 12
Sequence 1
Sequence 2
Sequence 3
Sequence 4
3 2 4 1
4 3 12
14 2 3
2 13 4
Since the niomber of treatments is even, either one of the two squares
formed creates a design balanced for one -period carryover effects.
In addition to designs balanced for one-period carryover, Williams
also considers designs balanced for two-period carryover effects. This
condition of balance requires all ordered triplets of treatments to
occur equally often in the design. Williams describes a construction
method based on sets of t-1 mutually orthogonal Latin squares where t is
an odd prime number or a power of a prime.
A model for analyzing a Williams square sequence structure without
adjustment for carryover effects incorporates sources of variation for
sequence, subjects within a sequence, period, treatment, and an error
term. A model is,
(4.1)
'ijkt 1 ^j(i) k t ijkt'
where the effects are defined as in model (2.3), excluding the carryover
terms.
The sources of variation with their respective degrees of freedom
for the analysis unadjusted for the carryover effects are in Table 4.
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Table 4. ANOVA Table for Williams Square Model with Unadjusted Treatment
Source of Variation df
Between Subject Analysis
Sequence s - 1
s
Subject(Sequence) S (n.-l)
1-1 ^
Within Subject Analysis
Period t - 1
Treatment t - 1
s
Error (S n.-l) (t-1) - (t-1)
i-1 ^
s
Total (S n ) t - 1
1-1 ^
This analysis does not take advantage of the balanced treatment
sequence structure of the Williams square design that is valuable in
measuring the effects due to carryover.
A model for analyzing a Williams square sequence structure in which
an adjustment for carryover effects is incorporated includes a sequence
by treatment interaction term. The sequence by treatment interaction
can be partitioned into (t-1) degrees of freedom period and (t-1)
degrees of freedom for one -period carryover with the remaining degrees
of freedom associated with other residual effects. The model with
carryover effects is,
yijkm- f^ ^ \ ^ ?j(i) + "k + V +
___f/m\(k-l)m
*=
* *
+ S A X., + e.
., , - (4 2)
. m ikm ijkm' i.'*-^;
m—
1
-
where ii - overall mean,
14
K. = effect of sequence i,
?.,.,- effect of subject j within sequence 1,
jr. - effect of period k,
T — effect of treatment t,
A - carryover effect of the treatment m occurring in the
previous period,
*
^mki ~ '^^si'i"^! effect (excluding one period carryover) from
period k in sequence i,
1 if treatment m occurs in period (k-1) of
^i(k-l)m - ( sequence 1,
otherwise,
1 if treatment m occurs in period (k-2) of
I
^i(k-2)m " \ sequence 1,
otherwise , and
«£jjj^ - random error of time period within an experimental unit.
The sources of variation and the associated degrees of freedom for the
analysis adjusted for carryover are given in Table 5.
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Table 5. ANOVA Table for Williams Square Model with Carryover Effects
Source of Variation df
Between Subject Analysis
Sequence s - 1
s
Subject(Sequence) 2 (n. - 1)
1-1 "
Within Subject Analysis
Period t - 1
Treatment t - 1
Sequence * Treatment
One -Period Carryover t - 1
Other Carryover (s-2) (t-1) - (t-1)
s
Error [(Sn.)-l] (t-1) - (s-1) (t-1)
i-1 ^
s
Total (S n ) t - 1
i-1 ^
5
.
Sequence by Treatment Interaction
The Williams square sequence structure was designed specifically to
address the problem of possible differential carryover effects for
experiments with three or more treatments. The sequence by treatment
interaction term in the two-period crossover design is equivalent to the
period effect. In a William square sequence structure with more than
two periods, the period effect is a partition of the sequence by
treatment interaction term. An experimenter choosing to use this
sequence structure would expect the effects of treatment to extend
beyond the period of application. Therefore, there are t-1 independent
apriorl comparisons involving one-period carryover effects. The sum of
squares associated with these t-1 comparisons is also a partition of the
16
sequence by treatment sxoms of squares. The remainder of the sequence by
treatment interaction is a lack of fit sum of squares associated with
residual effects that have not been accounted for with a design balanced
for only one-period carryover effects.
For each treatment In a three -treatment three-period crossover
design, there are six possible types of carryover effects. The
carryover effects associated with treatment A are,
i)
^A /ON • ^^^ carryover of treatment A from period one
affecting treatment B in period two
,
ii)
^f,(r) '^^ carryover of treatment A from period one
affecting treatment C in period two
iii)
^AfBO ' "^^ carryover of treatment A from period one
affecting treatment C in period three with treatment
B in period two,
Iv) \cr;R\ t^he carryover of treatment A from period one
affecting treatment B in period three with treatment
C in period two,
v)
•^(B)A('C')' ^^^
carryover of treatment A from period two
affecting treatment C in period three with
treatment B in period one, and
vi)
•^(c)A(B')' ''^^ carryover of treatment A from period two
affecting treatment B in period three with
treatment C in period one.
Incorporating a one-period carryover effect into a model assumes
that, for treatment A, X^ - X^^^^ = A^^^^ = X^^^^^^^ - A^^^^^^^
.
Similarly for treatments B and C, X^ - X^^^^ - X^^^^ - X^^^^^^^ -
\c)B(A) ^"^ ^C - ^C(B) - ^C(A) - \a)C(B) - \b)C(A)' respectively.
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Including a two-period carryover effect into a model assumes that,
for treatment A,
•^./dqn ~
^AfCBI ' Similarly for treatments B and C,
^B(AC) - ^B(CA) ^"'^ \(AB) " \(BA)' ^^^V^'^^i^^'^V The sums of squares
associated with the sequence by treatment interaction, after
partitioning out the sums of squares due to period and one -period
carryover, is a lack of fit measure of the deviation from the one-period
carryover model in (2.3).
In a Williams square sequence structure with six sequences, three
treatments, and five subjects per sequence, the sources of variation and
the degrees of freedom are given in Table 6.
Table 6. ANOVA Table for a Three-Period Williams Square Model
Source of Variation df
Between Subject Analysis
Sequence
Subject (Sequence)
Within Subject Analysis
Period
5
24
2
Treatment 2
Carryover
Sequence*Treatment
Error
2
6
48
In this example, the sequence by treatment interaction term has only six
degrees of freedom, instead of the expected ten degrees of freedom. Two
degrees of freedom correspond to the period effects and two degrees of
freedom to the one-period carryover effects. Six degrees of freedom
remain as a lack of fit test for the proposed model with one-period
carryover. If this test is insignificant, it implies that a model for
one-period carryover effects is adequate in describing the data. If
this term is significant, other carryover effects, such as two -period
18
carryover, bias the test for and the estimates of direct treatment
effects
.
5. Computer Analysis
In the preceding sections, a Williams square sequence structure
with an associated model and analysis of variance table was described in
which possible carryover effects were accounted for. In this section, a
computer code is presented for use with the SAS computer package to
conduct the analysis.
Tests of hypotheses for the main effects of sequence, period, and
treatment and the sequence by treatment interaction are obtained
directly from an application of the GLM procedure. However, a test for
differential one-period carryover effects cannot be obtained directly
since the appropriate partition of the design matrix cannot be
constructed through the CLASSES and MODEL statement. The condition of
no carryover effects in period one cannot be conveyed. A partition of
the design matrix for differential carryover is constructed outside the
GLM procedure and then passed in with the data.
Model (2.3) has more parameters than can be uniquely estimated.
One method of solving the normal equations for an overspecified model is
to constrain the parameters of the model. Three approaches for
restricting the carryover effect parameters are discussed. Each results
in the same overall test for carryover. The first method employs the
traditional sum- to-zero constraints. The second alternative is based on
set-to-zero constraints. Finally, the overparameterized model is
analyzed through contrasts. It is shown that information obtained
through the sum- to-zero and set-to-zero constraints can also be obtained
19
through the overparameterized model. A Williams square sequence
structure with three treatments is used as an example throughout the
discussions. With three treatments, there are two degrees of freedom
associated with carryover.
Sum-to-zero, the traditional constraint, requires the sum of the
t
carryover parameters to equal zero, i.e., S X. - 0. The source code to
construct the design matrix for carryover employing the sum-to-zero
restrictions is as follows, where the observed data are in a data set
called RAW_DATA.
DATA DESIGN_1; SET RAW_DATA;
RETAIN LAST_TRT;
SUM_l-0; SUM_2-0;
IF PERIOD NE 1 THEN DO;
IF LAST_TRT-1 THEN SUM_1-1
;
IF LAST_TRT-2 THEN SUM_2-1
IF LAST_TRT-3 THEN DO; SUM_1— 1; SUM_2— 1; END;
END;
LAST_TRT-TRT
;
For three treatments and three periods, there is a possibility of
carryover affecting treatment responses in periods two and three. The
indicator variables, SUM_1 and SUM_2 , are created to indicate the
treatment causing the carryover. SUM_1 equals 1 if the carryover is due
to treatment 1, SUM_2 equals 1 if the carryover is due to treatment 2,
and the sum-to-zero restriction forces both SUM_1 and SUM_2 to be -1 if
the carryover is caused by treatment 3. The GLM procedure is then used,
calling the DESIGN_1 data set. Since the design matrix for carryover
has been constructed in the previous data step, SUM_1 and SUM_2 are not
specified as classification variables in the CLASSES statement in GLM.
The source code is as follows.
20
PROC GLM DATA-DES1GN_1;
CLASSES SEQUENCE SUBJECT PERIOD TRT;
MODEL RESPONSE - SEQUENCE SUBJECT(SEQUENCE) PERIOD TRT SUM_1 SUM_2
;
The sum of squares corresponding to SUM_1 tests the hypothesis that
the carryover from treatment 1 is equal to the average of all the
carryover effects and the sum of squares corresponding to SUM_2 tests
the hypothesis that the carryover from treatment 2 is equal to the
average of all the carryover effects, i.e., H-iA.-A or H. : A..-1/2(A.+A,)
and K^:X^-X or Hg:A2-l/2(A^+A,)
, respectively. A contrast statement is
generated to test for equal carryover effects for all treatments, i.e.,
HgrA^-Aj-A,. For the sum-to-zero restriction, the contrast is as
follows
.
CONTRAST 'CARRYOVER' SUM_1 1 SUM_2 0,
SUM 1 SUM 2 1:
Set-to-zero constraints use restrictions that equate the last
parameter in each group equal to zero. The source code to construct the
design matrix for the carryover effects with the set-to-zero restriction
Is as follows, where the observed data are in the data set RAW_DATA.
DATA DESIGN_2; SET RAW_DATA;
RETAIN LAST_TRT;
SET_l-0; SET_2-0;
IF PERIOD NE 1 THEN DO;
IF LAST_TRT-1 THEN SET_1-1;
IF LAST_TRT-2 THEN SET_2-1;
END;
LAST_TRT-TRT
;
Similar to the sum- to-zero restrictions, SET_1 equals 1 if carryover is
due to treatment 1 , SET_2 equals 1 if carryover is due to treatment 2
,
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but the set- to -zero restriction forces both SET_1 and SET_2 to be zero
if carryover is caused by treatment 3
.
The GLM procedure is then used calling, the DESIGN_2 data set.
Since the design matrix for carryover has been constructed in the
previous data step, SET_1 and SET_2 are not specified as classification
variables in the CLASSES statement in GLM. The source code is as
follows
.
PROG GLM DATA-DESIGN_2
;
GLASSES SEQUENCE SUBJECT PERIOD TRT;
MODEL RESPONSE - SEQUENCE SUBJEGT(SEQUENCE) PERIOD TRT SET_1 SET_2;
The set-to-zero contrasts compare carryover from each treatment
effect with the carryover effect from the last treatment, the highest
coded level, i.e., H^rA^-A^ and Hq:A -A^. An overall test for
differential carryover, i.e., Hg:A^-A2-A2, can be tested using the
following contrast statement.
CONTRAST 'CARRYOVER' SET_1 1 SET_2 0,
SET_1 SET_2 1;
The overparameterized model imposes no constraints on the carryover
parameters. The source code to construct the design matrix for one-
period carryover effects for the overparameterized model Is as follows,
where again the observed data are in the data set called RAW_DATA.
DATA DESIGN_3; SET RAW_DATA;
RETAIN LAST_TRT;
Cl-0; C2-0; C3-0;
IF PERIOD NE 1 THEN DO;
IF LAST_TRT-1 THEN Cl-1
IF LAST_TRT-2 THEN C2-1
IF LAST_TRT-3 THEN C3-1
END;
LAST_TRT-TRT
;
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The parameters, CI, C2 , and C3 represent the carryover effects that are
caused by treatments 1, 2, and 3, respectively.
The GLM procedure Is then used, calling the DESIGN_3 data set.
Since the design matrix for carryover has been constructed in the
previous data step, CI, C2 , and C3 are not specified as classification
variables in the CLASSES statement in GLM. The source code is shown
below.
PROC GLM DATA-DESIGN_3;
CLASSES SEQUENCE SUBJECT PERIOD TRT;
MODEL RESPONSE - SEQUENCE SUBJECT (SEQUENCE) PERIOD TRT CI C2 C3
;
An overall test for differential carryover, i.e., H. :A..-;k -A,, is
tested through the following contrast statement.
CONTRAST 'CARRYOVER' CI 1 C2 -1 C3 0,
CI 1 C2 C3
-l',
CI C2 1 C3 -1;
7
.
Example
An example analysis for a three
-treatment Williams square design,
balanced for one-period carryover effects, is illustrated with the
overparameterized model. The data in Table 7 were generated with
subject variation of 10, error variance of 1, /i, - 5, /i„ - 5, andA B
/ij, - 6, and with carryover effects \ - -1, A - 0, and X - 1.
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Table 7. Data Generated with Williams Square Sequence Structure
TREATMENT PERIOD
SEQUENCE
ABC
SUBJECT 1 2 3
1 -2.127 -4.008 -0.832
2 7,778 5.976 6.862
3 9.304 7.348 11.476
4 5.495 5.900 8.063
5 2.066 0.742 3.212
1 4.160 4.684 2.647
2 -2.793 0.883 -1.706
3 8.969 8.611 10.388
4 2.169 2.207 2.263
5 10.183 12.089 12.374
1 11.196 12.655 10.228
2 3.769 5.442 1.516
3 4.910 4.333 1.757
4 7.128 7.397 4.206
5 7.363 6.955 5.252
1 1.818 4.849 1.990
2 9.109 12.065 10.098
3 0.887 -0.064 -0.539
4 7.929 8.430 6.498
5 4.205 3.813 5.285
1 8.598 7.036 10.065
2 7.458 6.977 7.922
3 -0.153
-1.197 1.241
4 3.286 1.147 3.762
5 0.968 3.509 4.184
1 9.445 6.823 8.583
2 5.698 7.125 5.971
3 4.694 4.654 5.759
4 6.966 6.956 7.259
5 3.949 2.893 2.202
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The analysis of variance table for the lack of fit test for the
data in Table 7 is reported in Table 8.
Source DF Tyoe I SS Mean Square F Value Pr > F
SEQUENCE 5 44.8624 8.9725 9.70 0.0001
SUBJECT (SEQUENCE) 24 1103.7853 45.9911 49.73 0.0001
PERIOD 2 0.2111 0.1055 0.11 0,8924
TRT 2 3.4055 1.7028 1.84 0.1697
CI 1 41.2620 41.2620 44.61 0.0001
C2 1 7.1565 7.1565 7.74 0.0077
C3 0.0000
SEQUENCE*TRT 6 4.1586 0.6931 0.75 0.6129
The hypothesis of lack of fit of the one-period carryover model is
not rejected (p - 0.6129). Thus, the one-period carryover model is
assumed to adequately describe the data.
For the analysis in Table 8, the contrast for one-period carryover
is not estimable nor are the adjusted treatment (least squares) means.
Next, a one-period carryover model without the sequence by
treatment interaction term is fit to the data in Table 7. The results
are displayed in Table 9. The Type I sum of squares for treatment is
the unadjusted treatment sum of squares while the Type III sum of
squares is the adjusted treatment sum of squares, adjusted for one-
period carryover effects.
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Table 9. ANOVA Table
Source DF Tvoe I SS Mean Sauare F Value Pr > F
SEQUENCE 5 44.8624 8.9725 9.98 0.0001
SUBJECT(SEQUENCE) 24 1103.7853 45.9911 51.15 0.0001
PERIOD 2 0.2111 0.1055 0.12 0.8895
TRT 2 3.4056 1.7028 1.89 0.1603
CI 1 41.2620 41.2620 45.89 0.0001
C2 1 7.1565 7.1565 7.96 0.0067
C3 0.0000
Source DF Tvoe III SS Mean Sauare F Value Pr > F
SEQUENCE 5 56.8253 11.3651 12.64 0.0001
SUBJECT(SEQUENCE) 24 1103.7853 45.9911 51.15 0.0001
PERIOD 1 0.0513 0.0513 0.06 0.8121
TRT 2 15.1933 7.5966 8.45 0.0006
CI 0.0000
C2 0.0000
C3 0.0000
Contrast DF Contrast SS Mean Sauare F Value Pr > F
CARRYOVER 2 48.418497 24.209249 26.93 0.0001
Significant differential one-period carryover effects (p < 0.0001)
are indicated by the contrast statement in Table 9. No significant
differences were found between the treatments before adjusting for the
carryover effects (p - 0.1603). However, significant treatment
differences (p - 0.0006) are detected using the Type III adjusted sum of
squares
.
The sum- to-zero hypotheses, i.e., B^-.X.-l/liX^+X.)
,
Ho:>2-l/2(^l+^3). and Hq:X^-1/2(.\^+X^) , are tested using the following
contrast statements through the overparameterized model.
CONTRAST 'Cl-CBAR' CI 2 C2 -1 C3 -1
CONTRAST 'C2-CBAR' CI -1 C2 2 C3 -1
CONTRAST 'C3-CBAR' CI -1 C2 -1 C3 2
The results for the data in Table 7 are reported in Table 10.
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Table 10. Contrasts of Carryover Effects From the Average Carryover
Contrast DF Contrast SS Mean Square F Value Pr > F
Cl-CBAR 1 41.261965 41.261965 45.89 0.0001
C2-CBAR 1 0.801041 0.801041 0.89 0.3494
C3-CBAR 1 30.564739 30.564739 33.99 0.0001
The set-to-zero hypotheses, H.:A..-A„, H.:A.-A,, andH„:A„-A,, are
tested using the following contrast statements through the
overparameterized model.
CONTRAST 'C1-C2' CI 1 C2 -1 C3
CONTRAST 'C1-C3' CI 1 C2 C3 -1
CONTRAST 'C2-C3' CI C2 1 C3 -1
The results for the data in Table 7 are reported in Table 11.
Table 1 1. Contrasts Comparing the Differences of Carryover Effects
DF Contrast SS Mean Square F Value Pr > F
1 17.853758 17.853758 19.86 0.0001
1 47.617456 47.617456 52.96 0.0001
1 7.156532 7.156532 7.96 0.0067
Contrast
CI C2
CI C3
C2 C3
A complete listing of the program used to generate and analyze the
data in Table 7 with a complete analysis output is provided in Appendix
A.
8. Means and Least Squares Means
When crossover designs are used to compare treatments, a test for
differential carryover effects is conducted. If significant, treatment
effects are adjusted for the differential carryover effects. When
carryover effects exist but the test for carryover is nonsignificant or
27
ignored in the estimation of treatment effects , the resulting treatment
estimates are biased for the differential carryover effects.
The expected value of the unadjusted means for treatments A, B, and
C for a Williams square involving three treatments are,
E(y^) - ;i + ^ + r^ + 1/2 (Ag+Aj,)
,
E(yj) - M + i^ + rg + 1/2 (A^+A^) , and
E(y^) - ;i + ; + r^ + 1/2 (A^+Ag) .
For the data presented in Table 7, the results of a multiple comparison
of the unadjusted means based on the ANOVA table reported in Table 9 is
given in Table 12. No significant treatment differences were detected,
agreeing with the results of the unadjusted (Type I) test for the
treatment reported in Table 9.
Table 12. Means for the Example Data
T tests (LSD) for variable: Y
Alpha- 0.05 df- 54 MSE- 0.899106
Critical Value of T- 2.00
Least Significant Difference- 0.4908
Means with the same letter are not significantly different.
T Grouping Mean N TRT
A 5.427 30 C
A
A 5.240 30 A
A
A 4.954 30 B
The expected value of the adjusted means (least square means) for
treatments A, B, and C are.
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E(y^) - M + T + r^ + 2/3 A ,
E(yg) - /J + Jr + Tg + 2/3 A , and
E(y^) ~ ^ + i + T^ + 2/3 A .
If differential carryover exists , the difference between two
adjusted means is an unbiased estimate of the difference between the
corresponding mean treatment effects. In contrast, the difference
between two unadjusted means is biased, as shown above.
For the data presented in Table 7, the results of a multiple
comparison of the adjusted least squares means based on the ANOVA table
reported in Table 9 is given in Table 13. Significant differences
between treatments A and C (p - .0002) and B and C (p - .0042) were
detected.
Table 13. Least Squares Means for the Example Data
TRT Y Std Err Pr > |T| LSMEAN
LSMEAN LSMEAN H0:LSMEAN-0 Number
A 4.76128263 0.18698995 0.0001 1
B 5.02081496 0.18698995 0.0001 2
C 5.83923682 0.18698995 0.0001 3
Pr > |T| HO: LSMEAN(i)-LSMEAN(j
)
1/j 1 2 3
1 . 0.3473 0.0002
2 0.3473
. 0.0042
3 0.0002 0.0042
9. Power Analysis - Williams Square versus Latin Square
Both a Latin square sequence structure and a Williams square
sequence structure can be used to assign treatments to sequences in
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constructing crossover designs, A Latin square sequence structure is
not balanced for one-period carryover. Thus, the power for detecting
one-period carryover effects is less than the power for a Williams
square sequence structure for the same number of subjects per design.
The sequence structures for both designs used in the power analysis are
given in Table 14.
Table 14. Sequence Structures Used in the Power Analvsls
Sequence 1
Sequence 2
Sequence 3
Williams Square
Sequence 4
Sequence 5
Sequence 6
Latin Square
Sequence 1
Sequence 2
Sequence 3
3 2 113 2
2 13
To compare the power of the Latin square sequence structure with
the Williams squares sequence structure, the following sets of treatment
means were specified with subject and error variances set to zero.
Treatment 1 Treatment 2 Treatment 3
Condition 1: 5 5 5
Condition 2: 5 5 6
Condition 3: 5 6 7
Each of these treatment combinations were paired with the following sets
of carryover effects.
Condition 1
Condition 2
Condition 3
Carryover 1
-1
-1
-1
Carryover 2
-1
-2
Carryover 3
1
2
3
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A program that computes the sums of squares necessary for the
computation of the noncentrality parameters needed for various tests of
hypotheses is given in Appendix B. The program to calculate the power
curve for detecting unadjusted treatment effects, adjusted treatment
effects, one-period carryover, and sequence by treatment interaction is
listed in Appendix C. The sums of squares obtained through the program
in Appendix B, which are given in Table 15, are used as input for the
power program in Appendix C.
Table 15
. Noncentrality Parameters With One Subject Per Sequence
Treatment Carryover Adjusted Treatment Differential Carryover
Effects Effects Williams Latin Williams Latin
5.33 0.67
16.00 2.00
37.33 4.67
5 6 -10 1 3.20 0.40 5.33 0.67
16.00 2.00
37.33 4.67
5 6 7 -10 1 9.60 1.20 5.33 0.67
16.00 2.00
37.33 4.67
-1 1 0.00 0.00
-1 -1 2 0.00 0.00
-1 -2 3 0.00 0.00
1
-1 -1 2 3.20 0.40
-1 -2 3 3.20 0.40
1
-1 -1 2 9.60 1.20
-1 -2 3 9.60 1.20
For each test of hypothesis, the sum of squares is multiplied in an
iterative manner over a range of sample sizes in order to calculate the
power curves.
The power of detecting unadjusted treatment differences, adjusted
treatment differences, and differential carryover for both the Latin
square sequence structure and the Williams square sequence structure for
the various conditions described above are reported in Tables 16 through
24 at the end of this section. The powers are graphically compared in
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Figures 1 through 15 immediately following the appropriate table. In
each case, the Williams square sequence structure is as powerful or more
powerful than the Latin square sequence structure. The 0.05 reported in
Tables 16, 17, and 18 indicate the null hypothesis of equal adjusted
treatment means is true. The 0.05 is interpreted as the level of
significance for the test. Similarly, the 0.05 reported in Table 20
indicates the null hypothesis of equal unadjusted treatment means for
the Williams square sequence structure is true. This is a consequence
of the particular combination of values chosen for treatment and
carryover effects and the balancing of the Williams square sequence
structure. Again, the 0.05 is interpreted as the level of significance
for the test.
The programs in Appendix B and C are useful for experiment planning
and as a classroom tool. Specific treatment effects, carryover effects,
and variances can be input to obtain sums of squares, which can then be
used to calculate the power of detecting treatment differences.
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Table 16
Power of Detecting Specified Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.3439 0.0500 0.1178
12 0.7702 0.0500 0.2505
18 0.9355 0.0500 0.3802
24 0.9845 0.0500 0.5007
30 0.9967 0.0500 0.6068
36 0.9993 0.0500 0.6964
42 0.9999 0.0500 0.7697
48 1.0000 0.0500 0.8279
54 1.0000 0.0500 0,8732
60 1.0000 0.0500 0.9077
66 1.0000 0.0500 0.9335
72 1.0000 0.0500 0.9526
78 1.0000 0.0500 0.9666
84 1.0000 0.0500 0.9766
90 1.0000 0.0500 0.9837
96 1.0000 0.0500 0.9888
102 1.0000 0.0500 0.9923
108 1.0000 0.0500 0.9948
114 1 . 0000 0.0500 0.9965
120 1.0000 0.0500 0.9976
Williams Square 6 0.1178 0.0500 0.3439
12 0.2505 0.0500 0.7702
18 0.3802 0.0500 0.9355
24 0.5007 0.0500 0.9845
30 0.6068 0.0500 0.9967
36 0.6964 0.0500 0.9993
42 0.7697 0.0500 0.9999
48 0.8279 0.0500 1.0000
54 0.8732 0.0500 1.0000
60 0.9077 0.0500 1.0000
66 0.9335 0.0500 1.0000
72 0.9526 0.0500 1.0000
78 0.9666 0.0500 1.0000
84 0.9766 0.0500 1.0000
90 0.9837 0.0500 1.0000
96 0.9888 0.0500 1.0000
102 0.9923 0.0500 1.0000
108 0.9948 0.0500 1.0000
114 0.9965 0.0500 1.0000
120 0.9976 0.0500 1.0000
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Figure 1
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Legend: — Latin Square Design
* - Williams Square Design
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Table 17
Power of Detecting Specified Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.7855 0.0500 0,2682
12 0.9979 0.0500 0,6387
18 1.0000 0.0500 0,8471
24 1.0000 0.0500 0,9422
30 1.0000 0.0500 0,9800
36 1.0000 0.0500 0,9935
42 1.0000 0.0500 0,9980
48 1.0000 0.0500 0,9994
54 1.0000 0.0500 0,9998
60 1.0000 0.0500 1,0000
66 1.0000 0.0500 1,0000
72 1.0000 0.0500 1,0000
78 1.0000 0.0500 1,0000
84 1.0000 0.0500 1.0000
90 1,0000 0.0500 1,0000
96 1.0000 0.0500 1,0000
102 1.0000 0.0500 1,0000
108 1.0000 0.0500 1,0000
114 1.0000 0,0500 1,0000
120 1.0000 0,0500 1,0000
Williams Square 6 0.2682 0,0500 0,7855
12 0.6387 0,0500 0,9979
18 0.8471 0,0500 1,0000
24 0.9422 0,0500 1,0000
30 0.9800 0,0500 1,0000
36 0,9935 0,0500 1,0000
42 0.9980 0,0500 1,0000
48 0,9994 0,0500 1,0000
54 0,9998 0,0500 1,0000
60 1,0000 0,0500 1,0000
66 1,0000 0,0500 1,0000
72 1.0000 0,0500 1,0000
78 1.0000 0,0500 1,0000
84 1.0000 0.0500 1,0000
90 1.0000 0.0500 1,0000
96 1.0000 0.0500 1,0000
102 1.0000 0.0500 1,0000
108 1.0000 0.0500 1,0000
114 1.0000 0.0500 1,0000
120 1.0000 0,0500 1 , 0000
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Figure 2
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 5
Carryover Effects; -1, -1, 2
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Table 18
Power of Detecting Specified Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.9880 0.0500 0.5496
12 1.0000 0.0500 0.9529
18 1.0000 0.0500 0.9967
24 1.0000 0.0500 0.9998
30 1.0000 0.0500 1.0000
36 1.0000 0.0500 1.0000
42 1.0000 0.0500 1.0000
48 1.0000 0.0500 1.0000
54 1.0000 0.0500 1.0000
60 1.0000 0.0500 1.0000
66 1.0000 0.0500 1.0000
72 1.0000 0.0500 1.0000
78 1.0000 0.0500 1.0000
84 1.0000 0.0500 1.0000
90 1.0000 0.0500 1.0000
96 1.0000 0.0500 1.0000
102 1.0000 0.0500 1.0000
108 1.0000 0.0500 1.0000
114 1.0000 0.0500 1 . 0000
120 1.0000 0.0500 1.0000
Williams Square 6 0.5496 0.0500 0.9880
12 0.9529 0.0500 1.0000
18 0.9967 0.0500 1.0000
24 0.9998 0.0500 1.0000
30 1.0000 0.0500 1.0000
36 1.0000 0.0500 1.0000
42 1.0000 0.0500 1.0000
48 1.0000 0.0500 1.0000
54 1.0000 0.0500 1.0000
60 1.0000 0.0500 1 . 0000
66 1.0000 0.0500 1.0000
72 1.0000 0.0500 1.0000
78 1.0000 0.0500 1.0000
84 1.0000 0.0500 1.0000
90 1.0000 0.0500 1.0000
96 1.0000 0.0500 1.0000
102 1.0000 0.0500 1.0000
108 1.0000 0.0500 1.0000
114 1.0000 0.0500 1 . 0000
120 1.0000 0.0500 1.0000
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Figure 3
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Table 19
Power of Detecting Specified Effect
Treatment Means: 5, 5, 6
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.5496 0.0897 0.1178
12 0.9529 0.1652 0.2505
18 0.9967 0.2421 0.3802
24 0.9998 0.3196 0.5007
30 1.0000 0.3955 0.6068
36 1,0000 0.4680 0.6964
42 1.0000 0.5359 0.7697
48 1.0000 0.5983 0.8279
54 1.0000 0.6548 0.8732
60 1.0000 0.7054 0.9077
66 1.0000 0.7501 0,9335
72 I. 0000 0.7892 0.9526
78 1.0000 0.8232 0.9666
84 1.0000 0.8524 0.9766
90 1.0000 0.8774 0.9837
96 1.0000 0,8986 0.9888
102 1.0000 0.9164 0.9923
108 1.0000 0.9314 0.9948
114 1.0000 0.9439 0.9965
120 1.0000 0.9543 0.9976
Williams Square 6 0.1178 0.2223 0.3439
12 0.2505 0.5375 0.7702
18 0.3802 0.7543 0.9355
24 0.5007 0.8805 0.9845
30 0.6068 0.9457 0.9967
36 0.6964 0.9767 0.9993
42 0.7697 0,9904 0.9999
48 0.8279 0,9962 1.0000
54 0.8732 0,9985 1.0000
60 0.9077 0,9995 1.0000
66 0.9335 0,9998 1.0000
72 0.9526 0,9999 1.0000
78 0.9666 1,0000 1.0000
84 0.9766 1,0000 1.0000
90 0.9837 1,0000 1.0000
96 0.9888 1,0000 1.0000
102 0.9923 1.0000 1 . 0000
108 0.9948 1.0000 1,0000
114 0.9965 1.0000 1,0000
120 0.9976 1.0000 1,0000
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Figure 4
Power of Detecting Adjusted Treatment Effect
Treatment Means : 5 , 5 , 6
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Figure 5
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 5
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Table 20
Power of Detecting Specified Effect
Treatment Means : 5 , 5 , 6
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0,05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.6604 0.0897 0.2682
12 0.9857 0.1652 0.6387
18 0.9996 0.2421 0.8471
24 1.0000 0.3196 0.9422
30 1.0000 0.3955 0.9800
36 1.0000 0.4680 0.9935
42 1.0000 0.5359 0.9980
48 1.0000 0.5983 0.9994
54 1.0000 0.6548 0.9998
60 1.0000 0.7054 1.0000
66 1.0000 0.7501 1.0000
72 1.0000 0.7892 1.0000
78 1.0000 0.8232 1.0000
84 1.0000 0.8524 1.0000
90 1.0000 0.8774 1.0000
96 1.0000 0.8986 1.0000
102 1.0000 0.9164 1.0000
108 1.0000 0,9314 1.0000
114 1.0000 0,9439 1.0000
120 1.0000 0,9543 1.0000
Williams Square 6 0.0500 0,2223 0.7855
12 0.0500 0,5375 0.9979
18 0.0500 0,7543 1.0000
24 0.0500 0,8805 1.0000
30 0.0500 0,9457 1.0000
36 0.0500 0,9767 1.0000
42 0.0500 0,9904 1.0000
48 0.0500 0,9962 1.0000
54 0.0500 0,9985 1.0000
60 0.0500 0,9995 1.0000
66 0,0500 0,9998 1.0000
72 0.0500 0,9999 1,0000
78 0.0500 1,0000 1,0000
84 0.0500 1,0000 1,0000
90 0,0500 1,0000 1,0000
96 0.0500 1.0000 1,0000
102 0.0500 1,0000 1.0000
108 0.0500 1,0000 1.0000
114 0.0500 1,0000 1.0000
120 0.0500 1.0000 1.0000
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Figure 6
Power of Detecting Adjusted Treatment Effect
Treatment Means : 5 , 5 , 6
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* — Williams Square Design
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Figure 7
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 6
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* — Williams Square Design
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Table 21
Power of Detecting Specified Effect
Treatment Means ; 5 , 5 , 6
Carryover Effects; -1, -2, 3
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.9349 0.0897 0,5496
12 1.0000 0.1652 0,9529
18 1.0000 0.2421 0,9967
24 1.0000 0.3196 0,9998
30 1.0000 0.3955 1,0000
36 1.0000 0.4680 1,0000
42 1.0000 0.5359 1,0000
48 1.0000 0.5983 1,0000
54 1.0000 0.6548 1,0000
60 1.0000 0.7054 1.0000
66 1.0000 0.7501 1.0000
72 1.0000 0.7892 1.0000
78 1.0000 0,8232 1.0000
84 1.0000 0,8524 1.0000
90 1.0000 0,8774 1.0000
96 1.0000 0,8986 1.0000
102 1.0000 0,9154 1.0000
108 1.0000 0.9314 1.0000
114 1.0000 0.9439 1.0000
120 1.0000 0.9543 1,0000
Williams Square 6 0.1178 0.2223 0.9880
12 0.2505 0.5375 1.0000
18 0.3802 0.7543 1.0000
24 0.5007 0.8805 1.0000
30 0.6068 0.9457 1.0000
36 0.6964 0.9767 1.0000
42 0.7697 0.9904 1.0000
48 0.8279 0.9962 1.0000
54 0.8732 0.9985 1.0000
60 0,9077 0,9995 1.0000
66 0.9335 0,9998 1,0000
72 0.9526 0,9999 1,0000
78 0.9666 1,0000 1,0000
84 0.9766 1,0000 1,0000
90 0.9837 1,0000 1,0000
96 0.9888 1,0000 1,0000
102 0.9923 1,0000 1,0000
108 0.9948 1,0000 1.0000
114 0.9965 1,0000 1.0000
120 0.9976 1.0000 1.0000
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Power of Detecting Adjusted Treatment Effect
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Figure 9
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 5 , 6
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Table 22
Power of Detecting Specified Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.5496 0.1768 0.1178
12 0.9529 0.4210 0.2505
18 0.9957 0.6216 0.3802
24 0.9998 0.7673 0.5007
30 1.0000 0.8639 0.6068
36 1.0000 0.9235 0.6964
42 1.0000 0.9584 0.7697
48 1.0000 0.9781 0.8279
54 1.0000 0.9887 0.8732
60 1.0000 0.9943 0.9077
66 1.0000 0.9972 0.9335
72 1.0000 0.9986 0.9526
78 1.0000 0.9993 0.9666
84 1.0000 0.9997 0.9766
90 1.0000 0.9999 0.9837
96 1.0000 0.9999 0.9888
102 1.0000 1.0000 0.9923
108 1.0000 1.0000 0.9948
114 1.0000 1.0000 0.9965
120 1.0000 1.0000 0,9976
Williams Square 6 0.3439 0.5617 0,3439
12 0.7702 0,9580 0,7702
18 0.9355 0.9973 0,9355
24 0.9845 0.9999 0,9845
30 0.9967 1.0000 0,9967
36 0.9993 1.0000 0.9993
42 0.9999 1.0000 0.9999
48 1.0000 1.0000 1.0000
54 1.0000 1.0000 1.0000
60 1.0000 1.0000 1.0000
66 1.0000 1.0000 1.0000
72 1.0000 1.0000 1.0000
78 1.0000 1.0000 1.0000
84 1.0000 1.0000 1.0000
90 1.0000 1.0000 1.0000
96 1.0000 1.0000 1.0000
102 1.0000 1.0000 1.0000
108 1.0000 1.0000 1.0000
114 1,0000 1.0000 1,0000
120 1.0000 1.0000 1,0000
48
Figure 10
Power of Detecting Adjusted Treatment Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Figure 11
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, 0, 1
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
18
--+ + + +-
36 54 72 90
Total Number of Subjects
50
108 126
Table 23
Power of Detecting Specified Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.2682 0.1768 0.2682
12 0.6387 0.4210 0.6387
18 0.8471 0.6216 0.8471
24 0.9422 0.7673 0.9422
30 0.9800 0.8639 0.9800
36 0.9935 0.9235 0.9935
42 0.9980 0.9584 0.9980
48 0.9994 0.9781 0.9994
54 0.9998 0.9887 0.9998
60 1.0000 0.9943 1.0000
66 1.0000 0.9972 1.0000
72 1.0000 0.9986 1.0000
78 1.0000 0.9993 1.0000
84 1.0000 0.9997 1.0000
90 1.0000 0.9999 1.0000
96 1.0000 0.9999 1.0000
102 1.0000 1.0000 1.0000
108 1.0000 1.0000 1.0000
114 1.0000 1.0000 1.0000
120 1.0000 1.0000 1.0000
Williams Square 6 0.2682 0.5617 0.7855
12 0.6387 0.9580 0.9979
18 0.8471 0.9973 1.0000
24 0.9422 0.9999 1.0000
30 0.9800 1 . 0000 1.0000
36 0.9935 1.0000 1.0000
42 0.9980 1.0000 1.0000
48 0.9994 1.0000 1.0000
54 0.9998 1.0000 1.0000
60 1.0000 1.0000 1.0000
66 1.0000 1.0000 1.0000
72 1.0000 1.0000 1.0000
78 1.0000 1.0000 1.0000
84 1.0000 1.0000 1.0000
90 1.0000 1.0000 1.0000
96 1.0000 1.0000 1.0000
102 1.0000 1.0000 1.0000
108 1.0000 1.0000 1.0000
114 1.0000 1.0000 1.0000
120 1.0000 1.0000 1.0000
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Figure 12
Power of Detecting Adjusted Treatment Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Legend; — Latin Square Design
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Figure 13
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, -1, 2
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
* - Williams Square Design
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Table 24
Power of Detecting Specified Effect
Treatment Means ; 5 , 6 , 7
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Experimental Total Unadjusted Adjusted
Design Subjects Treatment Treatment Carryover
Latin Square 6 0.5496 0.1768 0.5496
12 0.9529 0.4210 0.9529
18 0.9967 0.6216 0.9967
24 0.9998 0.7673 0.9998
30 1.0000 0.8639 1.0000
36 1.0000 0.9235 1.0000
42 1.0000 0.9584 1.0000
48 1.0000 0.9781 1.0000
54 1.0000 0.9887 1.0000
60 1.0000 0.9943 1.0000
66 1.0000 0.9972 1.0000
72 1.0000 0.9986 1.0000
78 1.0000 0.9993 1.0000
84 1.0000 0.9997 1.0000
90 1.0000 0.9999 1.0000
96 1.0000 0.9999 1.0000
102 1.0000 1.0000 1.0000
108 1.0000 1.0000 1.0000
114 1.0000 1.0000 1.0000
120 1.0000 1.0000 1.0000
Williams Square 6 0.3439 0.5617 0.9880
12 0.7702 0.9580 1.0000
18 0.9355 0.9973 1.0000
24 0.9845 0.9999 1.0000
30 0.9967 1.0000 1.0000
36 0.9993 1.0000 1.0000
42 0.9999 1.0000 1.0000
48 1.0000 1.0000 1.0000
54 1.0000 1.0000 1.0000
60 1.0000 1 . 0000 1.0000
66 1.0000 1.0000 1.0000
72 1.0000 1.0000 1.0000
78 1.0000 1.0000 1.0000
84 1.0000 1.0000 1.0000
90 1.0000 1.0000 1.0000
96 1.0000 1.0000 1.0000
102 1.0000 1.0000 1.0000
108 1.0000 1.0000 1.0000
114 1.0000 1.0000 1.0000
120 1.0000 1.0000 1.0000
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Power of Detecting Adjusted Treatment Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
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Figure 15
Power of Detecting Differential Carryover Effect
Treatment Means : 5 , 6 , 7
Carryover Effects: -1, -2, 3
Variance - 1.0, Alpha - 0.05
Legend: - Latin Square Design
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10 . Summary
To analyze a Williams square sequence structure balanced for one-
period carryover, the design matrix for the carryover effects must be
constructed. The first step in the analysis is to include a lack of fit
test for the one-period carryover model. A model fit using sequence,
subjects within sequence, period, treatment, carryover, and a sequence
by treatment interaction is appropriate for the lack of fit test. The
significance of this interaction term indicates whether the one-period
carryover model is adequate to describe the data. When the interaction
is significant a one-period analysis is appropriate. However, when the
interaction is insignificant the next step in the analysis is to check
the equality of the carryover effects through contrast statements. This
test for carryover determines the proper treatment comparisons. When
carryover effects are equal, treatment comparisons may be made using the
unadjusted treatment means. When differential carryover effects exist,
the least squares means provide the appropriate treatment comparisons.
A power analysis shows that experiments using the Williams square
sequence structure are more powerful than experiments using the Latin
square sequence structure for detecting adjusted treatment differences
and differential carryover effects where each experiment utilizes the
same total number of subjects.
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Appendix A
59
NOTE: Copyright(c) 1985,86,87 SAS Institute Inc., Gary, NC 27512-8000,
U.S.A.
NOTE: SAS (r) Proprietary Software Release 6.03
Licensed to KANSAS STATE UNIVERSITY, Site 11175001.
NOTE: AUTOEXEC processing completed.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
option nonumber nodate ls-72 ps-56 missing-
TITLEl 'Williams Square Analysis';
DATA A;
SEED_SEQ-0
SEED_SUB-98442
SEED_PER-0
SEED ERR-56613
VAR_SEQ- 0;
VAR_SUB- 10;
VAR_PER- 0;
VAR ERR- 1;
N_SUBJ-5
;
TRT_l-5
TRT_2-5
TRT 3-6
FC_1—
1
FC_2-
FC 3- 1
SC_l-0
SC_2-0
SC 3-0
ARRAY TRT_MEAN (3) TRT_1 TRT_2 TRT_3
;
ARRAY FC_OVER (3) FC_1 FC_2 FC_3
;
ARRAY SC_OVER (3) SC_1 SC_2 SC_3;
DO SEQUENCE-1 TO 6;
IF VAR_SEQ NE THEN E_SEQ-RANNOR(SEED
ELSE E_SEQ-0;
DO SUBJECT-1 TO N_SUBJ
;
IF VAR_SUB NE THEN E_SUBJ-RANNOR(SEED
ELSE E_SUBJ-0;
DO PERIOD-1 TO 3;
IF VAR_ERR NE THEN ERROR-RANNOR(SEED
ELSE ERROR-0;
IF SEQUENCE-1 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-2 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-3 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEqUENCE-4 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-5 THEN DO;
IF PERIOD-1 THEN
SEQ)*SQRT(VAR_SEQ)
;
i_SUB)*SQRT(VAR_SUB)
;
ERR)*SQRT(VAR_ERR)
TRT-1
TRT-2 RESID-1; END;
TRT-3 RESID-2; RESID2-1; END;
TRT-2
TRT-3 RESID-2; END;
TRT-1 RESID-3
;
RESID2-2; END;
TRT-3
TRT-1 RESID-3; END;
TRT-2 RESID-1; RESID2-3; END;
TRT-3
TRT-2 RESID-3; END;
TRT-1 RESID-2; RESID2-3; END;
TRT-1
60
90 observations and 28 variables.
1.63 minutes.
49 , IF PERIOD-2 THEN DO; TRT-3 ; RESID-1; END;
50 IF PERIOD-3 THEN DO; TRT-2 ; RESID-3; RESID2-1; END;
51 END;
52 IF SEQUENCE-6 THEN DO;
53 IF PERI0D=1 THEN TRT-2;
54 IF PERIOD-2 THEN DO; TRT-1 ; RESlD-2; END;
55 IF PERIOD-3 THEN DO; TRT-3; RESID-1; RESID2-2; END;
56 END;
57 IF PERIOD-1 THEN Y-E_SEq+E_SUBJ+TRT_MEAN{TRT)+ERROR;
58 ELSE IF PERIOD-2 THEN
59 Y-E_SEQ+E_SUBJ+TRT_MEAN ( TRT ) +FC_OVER ( RES ID ) +ERROR
;
60 ELSE IF PERIOD-3 THEN
61
Y-E_SEQ+E_SUBJ+TRT_MEAN ( TRT ) +FC_OVER ( RES ID ) +SC_OVER { RESID2 ) +ERROR
;
62 OUTPUT;
63 END;
64 END;
65 END;
66 run;
NOTE: The data set WORK. A has
NOTE: The DATA statement used
67 PROG SORT; BY PERIOD;
68 run;
NOTE: The data set WORK. A has 90 observations and 28 variables.
NOTE: The PROCEDURE SORT used 23.00 seconds.
69 DATA B; SET A; BY PERIOD;
70 RETAIN E_PER;
71 IF FIRST. PERIOD THEN DO;
72 IF VAR_PER NE THEN E_PER-RANNOR(SEED_PER)*SQRT(VAR_PER) ;
73 ELSE E_PER-0;
74 Y-Y+E_PER;
75 END;
76 run;
NOTE: The data set WORK.B has 90 observations and 29 variables.
NOTE: The DATA statement used 33.00 seconds.
77 PROC SORT DATA-B; BY SEQUENCE SUBJECT PERIOD;
78 run;
NOTE: The data set WOEtK.B has 90 observations and 29 variables.
NOTE: The PROCEDURE SORT used 23.00 seconds.
79 PROC PRINT SPLIT-'*'; BY SEQUENCE SUBJECT;
80 ID SEQUENCE SUBJECT;
81 VAR PERIOD TRT Y;
82 LABEL SEQUENCE- 'SEQUENCE* '
83 SUBJECT-' SUBJECT* '
84 PERIOD-' PERIOD* '
85 TRT- ' TREATMENT* '
86 Y-'RESPONSE* ';
87 FORMAT Y 7.3;
88 run;
NOTE: The PROCEDURE PRINT used 1,07 minutes.
89 PROC SORT DATA-B; BY SEQUENCE TRT;
90 run;
NOTE: The data set WORK.B has 90 observations and 29 variables.
NOTE: The PROCEDURE SORT used 22.00 seconds.
91 PROC SORT DATA-B; BY SEQUENCE SUBJECT PERIOD;
61
92 run;
NOTE: The data set UORK.B has 90 observations and 29 variables.
NOTE: The PROCEDURE SORT used 22.00 seconds.
93 DATA C; SET B;
94 RETAIN LAST_TRT;
95 Cl-0; C2-0; C3-0;
96 IF PERIOD NE 1 THEN DO;
97 IF LAST_TRT-1 THEN Cl-1;
98 IF LAST_TRT-2 THEN C2-1
99 IF LAST_TRT-3 THEN C3-1
100 END;
101 LAST_TRT-TRT;
102 run;
NOTE: The data set WORK.C has
NOTE: The DATA statement used 46.
103 PROC GLM DATA-C;
104 TITLE3 'Analysis Adjusted for Carryover Effects';
105 TITLE4 'Overparameterized Model'
;
106 CLASSES SEQUENCE SUBJECT PERIOD TRT;
107 MODEL Y - SEQUENCE SUBJECT(SEQUENCE) PERIOD TRT CI C2 C3
SEQUENCE*TRT;
90 observations
00 seconds.
and 33 variables.
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
NOTE
127
NOTE:
TEST H-SEQUENCE
run;
CONTRAST
E-SUBJECT(SEQUENCE)
;
CARRYOVER' CI
CI
1
1
1
1
'C1-C2' CI C2
'C1-C3' CI C2
'C2-C3' CI C2
'Cl-CBAR' CI 2 C2
'C2-CBAR' CI -1 C2
'C3-CBAR' CI -1 C2
'C1-C2' CI 1 C2
'C1-C3' CI 1
'C2-C3' CI
'Cl-CBAR' CI
'C2-CBAR' CI
'C3-CBAR' CI
/ LSD;
/ STDERR PDIFF
C2
C2
2 C2
-1 C2
-1 C2 -1 C3
CONTRAST
CONTRAST
CONTRAST
CONTRAST
CONTRAST
CONTRAST
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
MEANS TRT
LSMEANS TRT
run;
CONTRAST CARRYOVER is not estimable.
CONTRAST C1-C2 is not estimable.
CONTRAST C1-C3 is not estimable.
CONTRAST C2-C3 is not estimable.
CONTRAST Cl-CBAR is not estimable.
CONTRAST C2-CBAR is not estimable.
CONTRAST C3-CBAR is not estimable.
C1-C2 is not estimable.
C1-C3 is not estimable.
C2-C3 is not estimable.
Cl-CBAR is not estimable.
C2-CBAR is not estimable.
C3-CBAR is not estimable.
quit;
The PROCEDURE GLM used 4.17 minutes.
62
1 C3
C3
C3
DIVISOR-3
DIVISOR-3
DIVISOR-3
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
NOTE:
PROC GLM DATA-C;
TITLE3 'Analysis Adjusted for One-Period Carryover'
;
TITLE4 'Overparameterized Model'
;
CLASSES SEQUENCE SUBJECT PERIOD TRT
;
MODEL Y - SEQUENCE SUBJECT(SEQUENCE) PERIOD TRT CI C2 C3
;
TEST H-SEQUENCE E-SUBJECT(SEQUENCE)
run;
1 C2 -1 C3 0,
1 C2 C3 -1;
C2 -1 C3
C2
C2
2 C2
1 C2
CONTRAST 'CARRYOVER' CI
CI
1
1
CONTRAST 'C1-C2' CI
CONTRAST 'C1-C3' CI
CONTRAST 'C2-C3' CI
CONTRAST 'Cl-CBAR' CI
CONTRAST 'C2-CBAR' CI
CONTRAST 'C3-CBAR' CI -1 C2 -1
ESTIMATE 'C1-C2' CI 1 C2 -1
ESTIMATE 'C1-C3' CI 1 C2
ESTIMATE 'C2-C3' CI C2 1
ESTIMATE 'Cl-CBAR' CI 2 C2 -1
ESTIMATE 'C2-CBAR' CI -1 C2 2
ESTIMATE 'C3-CBAR' CI -1 C2 -1 C3
MEANS TRT / LSD;
LSMEANS TRT / STDERR PDIFF;
run;
quit;
The PROCEDURE GLM used 3.82 minutes.
-1
-1
-1
-1
2
-1
-1
-1 / DIVISOR-3
-1 / DIVISOR-3
2 / DIVISOR-3
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
NOTE:
NOTE:
168
169
Effects
170
171
172
173
174
175
176
177
178
DATA D; SET B; BY SEQUENCE SUBJECT;
RETAIN N MEAN;
IF FIRST. SUBJECT THEN DO;
N-0; MEAN-O;
END;
N-N+1
;
MEAN-MEAN+Y;
IF PERIOD-3 THEN DO;
MEAN-MEAN/N
;
IF TRT-1 THEN DO; Ll-O;
ELSE IF TRT-2 THEN DO; Ll-1/3
;
THEN DO; Ll-1/3;
L2-1/3; L3-1/3; END;
L2-0; L3-1/3; END;
L2-1/3; L3-0; END;ELSE IF TRT-
OUTPUT
;
END;
run;
The data set WORK.D
The DATA statement used 41.
PROC GLM DATA-D;
TITLE3 'Between Subject Estimation of One -Period Carryover
has 30 observations and 34 variables.
.00 seconds.
MODEL MEAN-Ll L2 L3 / SOLUTION;
run;
' CARRYOVERCONTRAST
CONTRAST
CONTRAST
CONTRAST
ESTIMATE
ESTIMATE
'L1-L2'
'L1-L3'
'L2-L3'
'L1-L2'
'L1-L3'
LI
LI
LI
LI
LI
LI
LI
L2
L2
L2
L2
L2 L3
63
L2
L2
-1
-1
-1
L3
L3 -1
179 ESTIMATE 'L2-L3' LI L2 1 L3 -1;
180 run;
181 quit;
NOTE: The PROCEDURE GLM used 1.42 minutes.
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Williams Square Analysis
SEQUENCE SUBJECT PERIOD TREATMENT RESPONSE
1 1
2
3
1
2
3
-2.127
-4.008
-0.832
2 1
2
3
1
2
3
7.778
5.976
6.862
3 1
2
3
1
2
3
9.304
7.348
11.476
4 1
2
3
1
2
3
5.495
5.900
8.063
5 1
2
3
1
2
3
2.066
0.742
3.212
2 1 1
2
3
2
3
1
4.160
4.684
2.647
2 2 1
2
3
2
3
1
-2.793
0.883
-1.706
2 3 1
2
3
2
3
1
8.969
8.611
10.388
2 4 1
2
3
2
3
1
2.169
2.207
2,263
2 5 1
2
3
2
3
1
10.183
12.089
12.374
3 1 1
2
3
3
1
2
11.196
12.655
10.228
3 2 1
2
3
3
1
2
3.769
5.442
1.516
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Williams Square Analysis
SEQUENCE SUBJECT
3
PERIOD
1
2
3
TREATMENT RESPONSE
3 3
1
2
4.910
4.333
1.757
3 4 1
2
3
3
1
2
7.128
7.397
4.206
3 5 1
2
3
3
1
2
7.363
6.955
5.252
4 1 1
2
3
3
2
1
1.818
4.849
1.990
4 2 1
2
3
3
2
1
9.109
12.065
10.098
4 3 1
2
3
3
2
0.887
-0.064
-0.539
4 4 1
2
3
3
2
1
7.929
8.430
6.498
4 5 X
2
3
3
2
1
4.205
3.813
5.285
5 1 1
2
3
1
3
2
8.598
7.036
10.065
5 2 1
2
3
1
3
2
7.458
6.977
7.922
5 3 1
2
3
1
3
2
-0.153
-1.197
1.241
5 4 1
2
3
1
3
2
3.286
1.147
3.762
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Williams Square Analysis
SEQUENCE SUBJECT
5
PERIOD
1
2
3
TREATMENT RESPONSE
5 1
3
2
0.968
3.509
4.184
6 1 1
2
3
2
1
3
9.445
6.823
8.583
6 2 1
2
3
2
1
3
5.698
7.125
5.971
6 3 1
2
3
2
1
3
4.694
4.654
5.759
6 4 1
2
3
2
1
3
6.966
6.956
7.259
6 5 1
2
3
2
1
3
3.949
2.893
2.202
67
Williams Square Analysis
Analysis Adjusted for Carryover Effects
Overpararaeterized Model
General Linear Models Procedure
Class Level Information
Class Levels Values
SEQUENCE 6 12 3 4 5 6
SUBJECT 5 12 3 4 5
PERIOD 3 12 3
TRT 3 12 3
Number of observations in data set — 90
68
Williams Square Analysis
Analysis Adjusted for Carryover Effects
Overparameterized Model
General Linear Models Procedure
Dependent Variable: Y
Sum of Mean
Source DF Squares Square F Value Pr > F
Model 41 1204.8416 29.3864 31.77 0.0001
Error 48 44.3931 0.9249
Corrected Total 89 1249.2347
R -Square C.V. Root MSE Y Mean
.964464 18.46886 0.9617 5.207111
Source DF Type I SS Mean Square F Value Pr > F
SEQUENCE 5 44.8624 8.9725 9.70 0.0001
SUBJECT(SEQUENCE) 24 1103.7853 45.9911 49.73 0.0001
PERIOD 2 0.2111 0.1055 0.11 0.8924
TRT 2 3.4056 1.7028 1.84 0.1697
CI 1 41.2620 41.2620 44.61 0.0001
C2 1 7.1565 7.1565 7.74 0.0077
C3 0.0000
SEQUENCE*TRT 6 4.1586 0,5931 0.75 0.6129
Source DF Type III SS Mean Square F Value Pr > F
SEQUENCE 5 56.8253 11.3651 12.29 0.0001
SUBJECT(SEQUENCE) 24 1103.7853 45.9911 49.73 0.0001
PERIOD 0.0000
TRT 2 15.1933 7.5966 8.21 0,0009
CI 0.0000
C2 0.0000
C3 0.0000
SEQUENCE*TRT 6 4.1586 0.6931 0.75 0.6129
Tests of Hypotheses using the Type III MS for
SUBJECT (SEQUENCE) as an error term
Source
SEQUENCE
DF Type III SS Mean Square F Value
5 56.825306 11.365061 0.25
Pr > F
0.9372
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Williams Square Analysis
Analysis Adjusted for Carryover Effects
Overparameterized Model
General Linear Models Procedure
T tests (LSD) for variable: Y
NOTE: This test controls the type I coniparlsonwise error rate not
the experimentwise error rate.
Alpha- 0.05 df- 48 MSE- 0.924856
Critical Value of T- 2.01
Least Significant Difference- 0.4993
Means with the same letter are not significantly different.
T Grouping Mean N TRT
A 5.427 30 3
A
A 5.240 30 1
A
A 4.954 30 2
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Williams Square Analysis
Analysis Adjusted for Carryover Effects
Overparameterized Model
General Linear Models Procedure
Least Squares Means
TRT Y
LSMEAN
1
2
3
Non-est
Non-est
Non-est
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Williams Square Analysis
Analysis Adjusted for One-Period Carryover
Overparameterized Model
General Linear Models Procedure
Class Level Information
Class Levels Values
SEQUENCE 6 12 3 4 5 6
SUBJECT 5 12 3 4 5
PERIOD 3 12 3
TRT 3 12 3
Number of observations in data set - 90
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Williams Square Analysis
Analysis Adjusted for One-Period Carryover
Overparameterized Model
General Linear Models Procedure
Dependent Variable: Y
Sum of Mean
Source DF Squares Square F Value Pr > F
Model 35 1200.6830 34.3052 38.15 0.0001
Error 54 48.5517 0.8991
Corrected Total 89 1249.2347
R -Square C.V. Root MSE Y Mean
.961135 18.20994 0.9482 5.207111
Source DF Type I SS Mean Square F Value Pr > F
SEQUENCE
SUBJECT (SEQUENCE)
PERIOD
TRT
CI
C2
C3
5
24
2
2
1
1
44.8624
1103.7853
0.2111
3.4056
41.2620
7.1565
0.0000
8.9725
45.9911
0.1055
1.7028
41.2620
7.1565
9.98
51.15
0.12
1.89
45.89
7.96
0.0001
0.0001
0,8895
0.1603
0.0001
0.0067
Source DF Type III SS Mean Square F Value Pr > F
SEQUENCE
SUBJECT (SEQUENCE)
PERIOD
TRT
CI
C2
C3
5
24
1
2
56.8253
1103.7853
0.0513
15.1933
0.0000
0.0000
0.0000
11.3651
45.9911
0.0513
7.5966
12.64
51.15
0.06
8.45
0.0001
0.0001
0.8121
0.0006
Tests of Hypotheses using the Type III MS for
SUBJECT(SEQUENCE) as an error term
Source
SEQUENCE
DF Type III SS Mean Square F Value
5 56.825306 11.365061 0.25
Pr > F
0.9372
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Williams Square Analysis
Analysis Adjusted for One-Period Carryover
Overparameterized Model
General Linear Models Procedure
T tests (LSD) for variable: Y
NOTE: This test controls the type I comparisonwise error rate not
the experimentwise error rate.
Alpha- 0,05 df- 54 MSE- 0.899106
Critical Value of T- 2.00
Least Significant Difference- 0.4908
Means with the same letter are not significantly different.
T Grouping Mean N TRT
A 5.427 30 3
A
A 5.240 30 1
A
A 4.954 30 2
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Williams Square Analysis
Analysis Adjusted for One-Period Carryover
Overparameterized Model
General Linear Models Procedure
Least Squares Means
TRT Y Std Err Pr > |T| LSMEAN
LSMEAN LSMEAN HO:LSMEAN-0 Number
1 4.76128263 0.18698995 0.0001 1
2 5.02081496 0.18698995 0.0001 2
3 5.83923682 0.18698995 0.0001 3
Pr > |T| HO: LSMEAN(i)-LSMEAN(J
)
i/j 1 2 3
1 . 0.3473 0.0002
2 0.3473
. 0.0042
3 0.0002 0.0042
NOTE: To ensure overall protection level, only probabilities associated
with pre-planned comparisons should be used.
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Williams Square Analysis
Analysis Adjusted for One-Period Carryover
Overparameterized Model
General Linear Models Procedure
Dependent Variable
Contrast
CARRYOVER
C1-C2
C1-C3
C2-C3
Cl-CBAR
C2-CBAR
C3-CBAR
Contrast SS Mean Square F Value Pr > F
48.418497
17.853758
47.617456
7.156532
41.261965
0.801041
30.564739
24.209249
17.853758
47.617456
7.156532
41.261965
0.801041
30.564739
26.93
19.86
52.96
7.96
45.89
0.89
33.99
0001
0001
0001
0067
0001
3494
0001
Parameter
C1-C2
C1-C3
C2-C3
Cl-CBAR
C2-CBAR
C3-CBAR
Estimate
-1.63647905
-2.67256776
-1.03608871
-1.43634894
0.20013011
1.23621882
T for HO:
Parameter—
-4.46
-7.28
-2.82
-6.77
0.94
5.83
Pr > |T|
0.0001
0.0001
0.0067
0.0001
0.3494
0.0001
Std Error of
Estimate
0.36724097
0.36724097
0.36724097
0.21202667
0.21202667
0.21202667
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Williams Square Analysis
Between Subject Estimation of One-Period Carryover Effects
General Linear Models Procedure
Number of observations in data set - 30
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Williams Square Analysis
Between Subject Estimation of One-Period Carryover Effects
General Linear Models Procedure
Dependent Variable: MEAN
Sum of Mean
Source DF Squares Square F Value Pr > F
Model 2 0.1626086 0.0813043 0.01 0.9943
Error 27 382.7199843 14.1748142
Corrected Total 29 382.8825929
R Square C.V. Root MSE MEAN Mean
000425 72.30391 3.7649 5.207111
Source
LI
L2
L3
Source
LI
L2
L3
Type I SS Mean Square F Value
0.1226750
0.0399336
0.0000000
0.1226750
0.0399336
0.01
0.00
Pr > F
0.9266
0.9581
Type III SS Mean Square F Value Pr > F
Parameter
INTERCEPT
LI
L2
L3
Estimate
5.206045778 B
0.272900963 B
-0.268105346 B
0.000000000 B
T for HO:
Parameter-0
2.52
0.05
-0.05
Pr > |T|
0.0178
0.9573
0.9581
Std Error of
Estimate
2.06214555
5.05120437
5.05120437
NOTE: The X'X matrix has been found to be singular and a generalized
inverse was used to solve the normal equations. Estimates
followed by the letter 'B' are biased, and are not unique
estimators of the parameters.
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Williams Square Analysis
Between Subject Estimation of One-Period Carryover Effects
General Linear Models Procedure
Dependent Variable: MEAN
Contrast DF Contrast SS Mean Square F Value Pr > F
CARRYOVER 2 0.1626086 0.,0813043 0.01 0.9943
L1-L2 1 0.1626043 0,,1626043 0.01 0.9155
L1-L3 1 0.0413750 0.,0413750 0.00 0.9573
L2-L3 1 0.0399336
T for HO1
;
0,,0399336
Pr > |T|
0.00
Std
0.9581
Error of
Parameter Estimate Parameter•-0 Estimate
L1-L2 .54100631 0. 11 0.9155 5. 05120437
L1-L3 .27290096 0. 05 0.9573 5. 05120437
L2-L3 -0 .26810535 -0. 05 0.9581 5. 05120437
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Appendix B
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option nornjmber nodate Is—72 ps=-56 missing-
TITLEl 'Williams Square Analysis';
DATA A;
SEED_SEQ-0; VAR_SEQ-
SEED_SUB-0; VAR_SUB-
SEED_PER-0; VAR_PER-
SEED ERR-0: VAR ERR-
N SUBJ-1;
TRT 1-5; FC 1—1; SC 1-0
TRT 2-5; FC 2- 0; SC 2-0
TRT 3-6; FC 3- 1; SC 3-0
ARRAY TRT_MEAN (3) TRT_1 TRT_2 TRT_3
;
ARRAY FC_OVER (3) FC_1 FC_2 FC_3
;
ARRAY SC_OVER (3) SC_1 SC_2 SC_3
DO SEQUENCE-1 TO 6;
IF VAR_SEQ NE THEN E_SEQ-RANNOR(SEED
ELSE E_SEQ-0;
DO SUBJECT-1 TO N_SUBJ
;
IF VAR_SUB NE THEN E_SUBJ-RANNOR(SEED
ELSE E_SUBJ-0;
DO PERIOD-1 TO 3;
IF VAR_ERR NE THEN ERROR-RANNOR(SEED
ELSE ERROR-0;
IF SEQUENCE-1 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-2 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-3 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO; TRT-1
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-4 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-5 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
END;
IF SEQUENCE-6 THEN DO;
IF PERIOD-1 THEN
IF PERIOD-2 THEN DO;
IF PERIOD-3 THEN DO;
SEQ)*SQRT(VAR_SEQ)
;
SUB)*SQRT(VAR_SUB)
;
ERR)*SQRT(VAR_ERR)
;
TRT-1
TRT-2 RESID-1; END;
TRT-3 RESID-2; RESID2-1; END;
TRT-2
TRT-3 RESID-2; END;
TRT-1 RESID-3; RESID2-2; END;
TRT-3
RESID-3; END;
TRT-2 RESID-1; RESID2-3; END;
TRT-3
TRT-2 RESID-3; END;
TRT-1 RESID-2
;
RESID2-3; END;
TRT-1
TRT-3 RESID-1; END;
TRT-2 RESID-3; RESID2-1; END;
TRT-2
TRT-1 RESID-2; END;
TRT-3 RESID-1;
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RESID2-2; END;
END;
IF PERIOD-1 THEN Y-E_SEQ+E_SUBJ+TRT_MEAN(TRT)+ERROR;
ELSE IF PERIOD-2 THEN
Y-E_SEQ+E_SUBJ+TRT_MEAN { TRT ) +FC_OVER ( RES ID ) +ERROR
;
ELSE IF PERIOD-3 THEN
Y-E_SEQ+E_SUBJ+TRT_MEAN { TRT ) +FC_OVER ( RES ID ) +SC_OVER ( RES ID2 ) +ERROR
;
OUTPUT;
END;
END;
END;
run;
PROC SORT; BY PERIOD;
run;
DATA B; SET A; BY PERIOD;
RETAIN E_PER;
IF FIRST. PERIOD THEN DO;
IF VAR_PER NE THEN E_PER-RANNOR(SEED_PER)*SQRT(VAR_PER)
;
ELSE E_PER-0;
Y-Y+E_PER;
END;
run;
FROG SORT DATA-B; BY SEQUENCE SUBJECT PERIOD;
run;
PROC PRINT SPLIT-'*'; BY SEQUENCE SUBJECT;
ID SEQUENCE SUBJECT;
VAR PERIOD TRT Y;
LABEL SEQUENCE-' SEQUENCE* '
SUBJECT-' SUBJECT* '
PERIOD- ' PERIOD* '
TRT- ' TREATMENT* '
Y-'RESPONSE* ';
FORMAT Y 7.3;
run;
PROC SORT DATA-B; BY SEQUENCE TRT;
run;
PROC SORT DATA-B; BY SEQUENCE SUBJECT PERIOD;
run;
DATA C; SET B;
RETAIN LAST_TRT;
Cl-0; C2-0; C3-0;
IF PERIOD NE 1 THEN DO;
IF LAST_TRT-1 THEN Cl-1;
IF LAST_TRT-2 THEN C2-1;
IF LAST_TRT-3 THEN C3-1;
END;
LAST_TRT-TRT
;
run;
PROC GLM DATA-C;
TITLES 'Analysis Adjusted for Carryover Effects';
TITLE4 'Overparameterized Model'
;
CLASSES SEQUENCE SUBJECT PERIOD TRT;
MODEL Y - SEQUENCE SUBJECT(SEQUENCE) PERIOD TRT CI C2 C3 SEQUENCE*TRT;
TEST H-SEQUENCE E-SUBJECT(SEQUENCE)
;
run;
CONTRAST 'CARRYOVER' CI 1 C2 -1 C3 0,
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CI 1 C2 C3 1
CONTRAST 'C1-C2' CI 1 C2 -1 C3
CONTRAST 'C1-C3' CI 1 C2 C3 -1
CONTRAST 'C2-C3' CI C2 1 C3 -1
CONTRAST 'Cl-CBAR' CI 2 C2 -1 C3 -1
CONTRAST 'C2-CBAR' CI 1 C2 2 C3 -1
CONTRAST 'C3-CBAR' CI 1 C2 -1 C3 2
ESTIMATE 'C1-C2' CI 1 C2 -1 C3
ESTIMATE 'C1-C3' CI 1 C2 C3 -1
ESTIMATE 'C2-C3' CI C2 1 C3 -1
ESTIMATE 'Cl-CBAR' CI 2 C2 -1 C3 -1 / DIVIS0R=3
ESTIMATE 'C2-CBAR' CI 1 C2 2 C3 -1 / DIVISOR-3
ESTIMATE 'C3-CBAR' CI 1 C2 -1 C3 2 / DIVISOR-3
MEANS TRT / LSD;
LSMEANS TRT / STDERR PDIFF;
run;
quit;
PROC GLM DATA-C;
TITLE3 'Analysis Adjusted for One-Period Carryover'
;
TITLE4 'Overparameterlzed Model'
;
CLASSES SEQUENCE SUBJECT PERIOD TRT;
MODEL Y - SEQUENCE SUBJECT(SEQUENCE) PERIOD TRT CI C2 C3
;
TEST H-SEQUENCE E-SUBJECT(SEQUENCE)
;
run;
CI 1 C2 -1 C3 0,
CI 1 C2 C3 -1;
'C1-C2' CI 1 C2 -1 C3
'C1-C3' CI 1 C2
'C2-C3' CI C2 1
'Cl-CBAR' CI 2 C2 -1
CONTRAST 'CARRYOVER'
CONTRAST
CONTRAST
CONTRAST
CONTRAST
CONTRAST
CONTRAST
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
ESTIMATE
CI -1
-1
C2
C2 -
C2 -1
C2
C2 1
2 C2 -
1 C2
1 02 -
'C2-CBAR
'C3-CBAR' CI
'C1-C2' CI 1
'C1-C3' CI 1
'C2-C3' CI
'Cl-CBAR' CI
'C2-CBAR' CI
'C3-CBAR' CI
MEANS TRT / LSD;
LSMEANS TRT / STDERR PDIFF
run;
quit;
DATA D; SET B
RETAIN N MEAN;
IF FIRST. SUBJECT THEN DO;
N-0; MEAN-0;
END;
N-N+1
;
MEAN-MEAN+Y;
IF PERIOD-3 THEN DO;
MEAN-MEAN/N;
IF TRT-1 THEN DO; Ll-0
;
ELSE IF TRT-2 THEN DO; Ll-1/3
ELSE IF TRT-3 THEN DO; Ll-1/3
OUTPUT
;
DIVISOR-3
DIVISOR-3
DIVISOR-3
BY SEQUENCE SUBJECT;
-1/3; L3-1/3
;
END
-0; L3-1/3; END
-1/3; L3-0; END
83
END;
run;
PROC GLM DATA-D;
TITLE3 'Between Subject Estimation of One-Period Carryover Effects'
MODEL MEAN-Ll L2 L3 / SOLUTION;
run;
CONTRAST ' CARRYOVER LI 1 L2 -1
Li 1 L2
L3 ,
L3 -1;
CONTRAST 'L1-L2' LI 1 L2 -1 L3
CONTRAST 'L1-L3' LI 1 L2 L3 -1
CONTRAST 'L2-L3' LI L2 1 L3 -1
ESTIMATE 'L1-L2' LI 1 L2 -1 L3
ESTIMATE 'L1-L3' LI 1 L2 L3 -1
ESTIMATE 'L2-L3' LI L2 1 L3 -1
run;
quit;
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Appendix C
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titlel 'Power Analysis';
%let trt-%str( 5, 5, 6);
%let carry-%str(-l, -1, 2);
%let var-1.0;
%let alpha-0.05;
option nodate nonumber Is—72 ps-58 missing=' '
;
proc format;
value t_code l-'Unadjusted Treatment'
2-'Adjusted Treatment'
3-' Carryover'
4-' Sequence by Treatment';
value $d_code '0'— 'Latin Square'
'*'-'Williams Square'
;
run;
data a;
var — &var;
alpha — &alpha;
input test num_df ws Is;
label-'O'
;
n_seq — 3
n_per - 3
n_trt - 3;
If Is ne 0.0 then do n_subj - 2 to 40 by 2
;
n_total — n_seq*n_subj
;
err_df - n_total*(n_trt-l) - (n_per-l) - 2*(n_trt-l);
lambda - n_subj*ls/var;
if lambda gt 44.0 then lambda-44.0;
f - flnv( (1.0- alpha), num_df,err_df,0);
power - l-probf(f,num_df,err_df, lambda)
;
if lambda-44.0 then power - 1.0;
output;
end;
label-'*'
n_seq - 6
n_per - 3
n_trt - 3;
if ws ne 0.0 then do n_subj - 1 to 20;
n_total - n_seq*n_subj
;
resid_df - (n_seq-l)*(n_trt-l) - (n_per-l) - (n_trt-l)
;
err_df - n_total*(n_trt-l) - (n_per-l) - 2*(n_trt-l);
if test eq 4 then err_df - err_df - resid_df;
lambda - n_subj *ws/var
if lambda gt 44,0 then lambda-44.0;
f - finv((1.0-alpha) ,num_df,err_df ,0);
power - l-probf(f,num_df,err_df .lambda)
if lambda-44.0 then power — 1.0;
output
;
end;
keep test label n_total power;
* test l-'Unadjusted Treatment'
2- 'Adjusted Treatment'
3- 'Carryover'
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4-' Sequence by Treatment';
cards
;
1 2
2 2
3 2
4 6
run;
data al; set a;
if test-1;
rename power—unadj
;
run;
data a2 ; set a;
if test-2;
rename power-adj
;
run;
data a3; set a;
if test-3;
rename power-carry;
run;
data a4; set a;
if test-4;
rename power-seq_trt;
run;
data aa; merge al a2 a3 a4;
by label n_total notsorted;
run;
proc print split-'*' data-aa; by label notsorted;
tltlel 'Table ##'
;
title3 'Power of Detecting Specified Effect';
titles " Treatment Means: itrt"
;
title6 "Carryover Effects: Scarry";
title? " Variance - &var, Alpha - &alpha"
;
id label;
var n_total unadj adj carry seq_trt;
label label-' Experimental*Design* '
n_total-' Total*Subj ects* '
unadj -'Unadj usted*Treatment* '
adj -
' Adj usted*Treatment* '
carry-' Carryover* '
seq_trt-' Sequence by*Treatment* '
;
format label $d_code. unadj adj carry seq_trt 6.4;
run;
proc plot data-a nolegend; by test;
titlel 'Figure ##'
;
titles 'Power of Detecting Specified Effect';
titles " Treatment Means: &trt"
;
title6 "Carryover Effects: Scarry";
title? " Variance - &var, Alpha - &alpha"
;
title9 'Legend: - Latin Square Design ';
titlelO ' * - Williams Square Design'
;
plot power*n_total-label / vaxis-0.0 to 1.0 by .2;
label power-' Power'
n_total-'Total Number of Subjects';
format test t_code.;
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run;
quit;
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When different treatments are applied in succession to the same
subject, it is necessary to determine if there is carryover effect, an
effect of the preceding treatment on the current treatment, A Williams
square sequence structure, which is balanced for one-period carryover
effects, is defined with a discussion of a detailed analysis using the
SAS system. A power analysis shows that experiments using the Williams
square sequence structure are more powerful than experiments using the
Latin square sequence structure for detecting adjusted treatment
differences and differential carryover effects where each experiment
utilizes the same total niimber of subjects.
